Cryopyrin-Associated Periodic Syndrome Serum
Cryopyrin-Associated Periodic Syndrome Serum from donors with confirmed CAPS, a monogenic autoinflammatory disease caused by gain-of-function NLRP3 variants and constitutive inflammasome activation. Useful for IL-1beta and IL-18 quantification, acute-phase protein measurement, and pharmacodynamic work on IL-1-directed biologics. Stratification by FCAS, MWS, or NOMID phenotype and flare status; matched healthy controls available.
Cryopyrin-Associated Periodic Syndrome Serum for Autoinflammatory Disease Research
Our CAPS Serum is sourced from IRB-consented donors clinically diagnosed with cryopyrin-associated periodic syndrome (CAPS) and processed and frozen within 24 hours of collection to preserve cytokines, acute-phase proteins, and metabolites. CAPS is a monogenic autoinflammatory disease of innate immunity – it is not autoimmune, and there are no disease-defining autoantibodies – and serum is the appropriate matrix for its IL-1-driven soluble mediators.
CAPS Biology and Why Serum
- CAPS is caused by gain-of-function variants in NLRP3, which encodes the innate immune sensor cryopyrin. The mutant protein assembles the NLRP3 inflammasome constitutively or at an inappropriately low activation threshold.
- Inflammasome assembly activates caspase-1, which cleaves pro-IL-1beta and pro-IL-18 into their mature, secreted forms and triggers gasdermin D-mediated inflammatory cell death. IL-1beta is the credible, mechanistically central serum-side analyte.
- Because the defect lies in innate sensing, CAPS involves no autoantigen, no autoreactive lymphocyte clone, and no autoantibody production. Adaptive-immunity framing does not apply to this disease.
- The clinical spectrum spans three overlapping phenotypes of increasing severity: familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease (NOMID/CINCA), with urticaria-like rash, fever, arthralgia, and in severe forms sensorineural hearing loss and neurological involvement.
- Sustained IL-1 activity drives high circulating acute-phase reactants including CRP and serum amyloid A, and chronic SAA elevation carries a risk of secondary AA amyloidosis. The dramatic response to IL-1 blockade with anakinra, canakinumab, or rilonacept confirms the pathway.
- Serum is acellular and is the correct matrix for IL-1beta, IL-18, IL-6, CRP, and SAA measurement by immunoassay, and for proteomic work. Inflammasome activation assays require the paired cellular products.
Donor Stratification Available
- Clinical phenotype: FCAS, Muckle-Wells syndrome, or NOMID/CINCA
- NLRP3 genotype where genetic testing is documented, including somatic mosaicism cases
- Disease state at collection: active flare versus inter-flare or controlled disease
- Treatment status: IL-1 blockade-naive versus anakinra, canakinumab, or rilonacept treated
- Organ involvement: sensorineural hearing loss, ocular involvement, or documented AA amyloidosis
- Age band, including paediatric versus adult donors, and cold-exposure trigger history
- Matched healthy controls available
Product Features
- Collected from clinically confirmed cryopyrin-associated periodic syndrome donors
- Processed and frozen within 24 hours of collection
- Research Use Only (RUO)
- IRB-approved protocols with documented consent
- Standard and custom aliquot volumes available
De-identified Donor Data
- Diagnosis confirmation, including genetic confirmation where available
- Age, sex assigned at birth, and ethnicity
- Donor-reported medical history and comorbidities
- CAPS phenotype, flare status, and IL-1 blockade treatment history where documented
- Additional CAPS-specific metadata available on request
Applications
- IL-1beta and IL-18 quantification as direct readouts of inflammasome activity
- Downstream cytokine profiling, including IL-6, TNF, and IL-1 receptor antagonist
- Acute-phase protein measurement, including CRP and serum amyloid A for amyloidosis risk research
- Pharmacodynamic and target-engagement assay development for IL-1-directed biologics
- Flare versus inter-flare biomarker discovery and disease-activity index development
- Untargeted serum proteomics and metabolomics of chronic innate inflammation
- Comparative studies against other monogenic autoinflammatory syndromes and against polygenic inflammatory disease
- Diagnostic assay development, reference-range establishment, and platform bridging for rare-disease panels
Other Cryopyrin-Associated Periodic Syndrome Specimen Types
- Cryopyrin-Associated Periodic Syndrome Plasma
- Cryopyrin-Associated Periodic Syndrome Whole Blood
- Cryopyrin-Associated Periodic Syndrome PBMC
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Cryopyrin-associated periodic syndrome serum is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To compare donor availability across conditions, visit our human serum page.
Protocols & Documentation
-
Download
Serum Isolation
Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Serum
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Serum cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.